Principia Biopharma, a Sanofi Company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Principia Biopharma, a Sanofi Company sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Principia Biopharma, a Sanofi Company: 8 sponsored US clinical trials, none currently recruiting.

Principia Biopharma, a Sanofi Company sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immune Thrombocytopenia, with 1 trials.

Upper-quartile sponsor footprint

Principia Biopharma, a Sanofi Company sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

NCT04562766
COMPLETED Phase 2

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
COMPLETED Phase 1

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

NCT06444191
COMPLETED Phase 1

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204
COMPLETED Phase 2

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

NCT04520451
TERMINATED Phase 3

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
COMPLETED Phase 2

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

NCT03395210
TERMINATED Phase 1

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

NCT02608125

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 2

Therapeutic Areas

Immune Thrombocytopenia 1

How the Principia Biopharma, a Sanofi Company early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Immune Thrombocytopenia (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Principia Biopharma, a Sanofi Company: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Principia Biopharma, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Principia Biopharma, a Sanofi CompanyAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Principia Biopharma, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Principia Biopharma, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Principia Biopharma, a Sanofi Company page

8 registered trials is a research-attention snapshot, not an endorsement of Principia Biopharma, a Sanofi Company or any single study.

  • None of Principia Biopharma, a Sanofi Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Immune Thrombocytopenia is the condition Principia Biopharma, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immune Thrombocytopenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Principia Biopharma, a Sanofi Company pipeline card: 8 registered trials from official public datasets.Report a data error.